Health Economics›Urothelial carcinoma›Locally advanced or metastatic disease refractory/intolerant to platinum chemotherapy

Locally advanced or metastatic disease refractory/intolerant to platinum chemotherapy

Urothelial carcinoma · 16 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	10.0 mo	—	—	1
Enfortumab vedotin and Pembrolizumab Variant #01 Partial	—	R 81 987	21d	~12.5 mo	~32.7 mo	~19	~R 1 557 757 PFS proxy · indirect	4
Docetaxel and Ramucirumab Variant #01	—	R 61 872	21d	4.8 mo	—	7	R 433 101 PFS proxy	1
nab-Paclitaxel monotherapy Variant #01	—	R 45 710	28d	~5.5 mo	~16.2 mo	~6	~R 274 259 PFS proxy · indirect	17
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	—	—	—	—	1
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	—	8.9 mo	—	—	4
MVAC Variant #01	—	R 1 082	28d	—	~15.3 mo	—	—	4
Gemcitabine and Paclitaxel N/A - secondary systemic drug	—	R 263	28d	—	7.8 mo	—	—	—
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	2.8 mo	8.9 mo	4	R 973 PFS proxy	6
Pemetrexed monotherapy N/A - secondary systemic drug	—	R 69	21d	~3.0 mo	~9.0 mo	~5	~R 347 PFS proxy · indirect	21
Avelumab monotherapy N/A - secondary systemic drug	—	R 0	28d	—	~22.6 mo	—	—	2
Erdafitinib monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Toripalimab monotherapy Variant #01 Partial	—	—	14d	—	—	—	—	—
Vinflunine monotherapy Variant #01 Partial	—	—	21d	—	8.0 mo	—	—	4
Tislelizumab monotherapy Variant #01 Partial	—	—	21d	—	~16.0 mo	—	—	3
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	~72.3 mo	—	—	2

16 of 16 regimens shown